Allurion Shares Jump on Weight-Loss Study Results

Dow Jones

2025/05/28

By Dean Seal

Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage.

The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday.

The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%.

The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 27, 2025 17:44 ET (21:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538973204"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538973204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538973204?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538973204","market":"us","top_or_hot":-1,"title":"Allurion Shares Jump on Weight-Loss Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n</p>\n<p>\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n</p>\n<p>\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n</p>\n<p>\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Shares Jump on Weight-Loss Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Shares Jump on Weight-Loss Study Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-28 05:44</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n</p>\n<p>\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n</p>\n<p>\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n</p>\n<p>\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消費者服務","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538973204","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538973204","pubTimestamp":1748382240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage.The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday.The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%.The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","ALUR":"Allurion Technologies Inc."},"translate_title":"Allurion股价因减肥研究结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9},"content_text":"By Dean Seal \n\n\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n\n\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n\n\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n\n\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 17:44 ET (21:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}